Inhibitory effect of aqueous dandelion extract on HIV-1 replication and reverse transcriptase activity

BMC Complementary and Alternative Medicine

Volumn 11, Issue , 2011, Pages

  Han, Huamin ^a,b   He, Wen ^a,b,d   Wang, Wei ^a,c   Gao, Bin ^a  

^a INSTITUTE OF MICROBIOLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^d HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DANDELION EXTRACT; PLANT EXTRACT; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DANDELION; DOSE RESPONSE; DRUG EFFECT; DRUG IDENTIFICATION; DRUG ISOLATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MOUSE; NONHUMAN; VIRUS INHIBITION; VIRUS REPLICATION; ANIMAL; CELL LINE; CHEMISTRY; ENZYMOLOGY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; PHYSIOLOGY; VIROLOGY;

ANIMALS; CELL LINE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MICE; PLANT EXTRACTS; REVERSE TRANSCRIPTASE INHIBITORS; TARAXACUM; VIRUS REPLICATION;

EID: 81055134738     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/1472-6882-11-112     Document Type: Article

References (41)

1. Cohen J. AIDS research. Promising AIDS vaccine's failure leaves field reeling. Science 2007, 318:28-29. 10.1126/science.318.5847.28, 17916696.
2. Shafer RW, Schapiro JM. HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev 2008, 10:67-84. 2547476, 18615118.
3. Vo TS, Kim SK. Potential Anti-HIV Agents from Marine Resources: An Overview. Mar Drugs 2010, 8:2871-2892. 10.3390/md8122871, 3039460, 21339954.
4. Jiang Y, Ng TB, Wang CR, Zhang D, Cheng ZH, Liu ZK, Qiao WT, Geng YQ, Li N, Liu F. Inhibitors from natural products to HIV-1 reverse transcriptase, protease and integrase. Mini Rev Med Chem 2010, 10:1331-1344. 10.2174/138955710793564133, 21175425.
5. Filho JR, de Sousa Falcao H, Batista LM, Filho JM, Piuvezam MR. Effects of plant extracts on HIV-1 protease. Curr HIV Res 2010, 8:531-544. 10.2174/157016210793499204, 20946094.
6. Park IW, Han C, Song X, Green LA, Wang T, Liu Y, Cen C, Yang B, Chen G, He JJ. Inhibition of HIV-1 entry by extracts derived from traditional Chinese medicinal herbal plants. BMC Complement Altern Med 2009, 9:29. 10.1186/1472-6882-9-29, 2736925, 19656383.
7. Singh IP, Bodiwala HS. Recent advances in anti-HIV natural products. Nat Prod Rep 2010, 27:1781-1800. 10.1039/c0np00025f, 20976350.
8. Asres K, Seyoum A, Veeresham C, Bucar F, Gibbons S. Naturally derived anti-HIV agents. Phytother Res 2005, 19:557-581. 10.1002/ptr.1629, 16161055.
9. Balestrieri E, Pizzimenti F, Ferlazzo A, Giofre SV, Iannazzo D, Piperno A, Romeo R, Chiacchio MA, Mastino A, Macchi B. Antiviral activity of seed extract from Citrus bergamia towards human retroviruses. Bioorg Med Chem 2011,
10. Kashiwada Y, Hashimoto F, Cosentino LM, Chen CH, Garrett PE, Lee KH. Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents. J Med Chem 1996, 39:1016-1017. 10.1021/jm950922q, 8676334.
11. Qian K, Yu D, Chen CH, Huang L, Morris-Natschke SL, Nitz TJ, Salzwedel K, Reddick M, Allaway GP, Lee KH. Anti-AIDS agents. 78. Design, synthesis, metabolic stability assessment, and antiviral evaluation of novel betulinic acid derivatives as potent anti-human immunodeficiency virus (HIV) agents. J Med Chem 2009, 52:3248-3258. 10.1021/jm900136j, 2736638, 19388685.
12. Kanamoto T, Kashiwada Y, Kanbara K, Gotoh K, Yoshimori M, Goto T, Sano K, Nakashima H. Anti-human immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation. Antimicrob Agents Chemother 2001, 45:1225-1230. 10.1128/AAC.45.4.1225-1230.2001, 90447, 11257038.
13. Smith PF, Ogundele A, Forrest A, Wilton J, Salzwedel K, Doto J, Allaway GP, Martin DE. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3', 3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob Agents Chemother 2007, 51:3574-3581. 10.1128/AAC.00152-07, 2043264, 17638699.
14. Sun IC, Chen CH, Kashiwada Y, Wu JH, Wang HK, Lee KH. Anti-AIDS agents 49. Synthesis, anti-HIV, and anti-fusion activities of IC9564 analogues based on betulinic acid. J Med Chem 2002, 45:4271-4275. 10.1021/jm020069c, 12213068.
15. Wang RR, Gu Q, Yang LM, Chen JJ, Li SY, Zheng YT. Anti-HIV-1 activities of extracts from the medicinal plant Rhus chinensis. J Ethnopharmacol 2006, 105:269-273. 10.1016/j.jep.2005.11.008, 16368204.
16. Chen X, Yang L, Zhang N, Turpin JA, Buckheit RW, Osterling C, Oppenheim JJ, Howard OM. Shikonin, a component of chinese herbal medicine, inhibits chemokine receptor function and suppresses human immunodeficiency virus type 1. Antimicrob Agents Chemother 2003, 47:2810-2816. 10.1128/AAC.47.9.2810-2816.2003, 182643, 12936978.
17. Genois N, Barbeau B, Olivier M, Tremblay MJ. Inhibition of HIV-1-mediated syncytium formation and virus replication by the lipophosphoglycan from Leishmania donovani is due to an effect on early events in the virus life cycle. Clin Exp Immunol 2001, 124:32-42. 10.1046/j.1365-2249.2001.01492.x, 1906040, 11359440.
18. Woods-Panzaru S, Nelson D, McCollum G, Ballard LM, Millar BC, Maeda Y, Goldsmith CE, Rooney PJ, Loughrey A, Rao JR, Moore JE. An examination of antibacterial and antifungal properties of constituents described in traditional Ulster cures and remedies. Ulster Med J 2009, 78:13-15. 2629014, 19252724.
19. Odintsova TI, Rogozhin EA, Sklyar IV, Musolyamov AK, Kudryavtsev AM, Pukhalsky VA, Smirnov AN, Grishin EV, Egorov TA. Antifungal activity of storage 2S albumins from seeds of the invasive weed dandelion Taraxacum officinale Wigg. Protein Pept Lett 2010, 17:522-529. 10.2174/092986610790963591, 19594427.
20. Koh YJ, Cha DS, Ko JS, Park HJ, Choi HD. Anti-inflammatory effect of Taraxacum officinale leaves on lipopolysaccharide-induced inflammatory responses in RAW 264.7 cells. J Med Food 13:870-878.
21. Park CM, Cha YS, Youn HJ, Cho CW, Song YS. Amelioration of oxidative stress by dandelion extract through CYP2E1 suppression against acute liver injury induced by carbon tetrachloride in Sprague-Dawley rats. Phytother Res 24:1347-1353.
22. You Y, Yoo S, Yoon HG, Park J, Lee YH, Kim S, Oh KT, Lee J, Cho HY, Jun W. In vitro and in vivo hepatoprotective effects of the aqueous extract from Taraxacum officinale (dandelion) root against alcohol-induced oxidative stress. Food Chem Toxicol 48:1632-1637.
23. Clare BA, Conroy RS, Spelman K. The diuretic effect in human subjects of an extract of Taraxacum officinale folium over a single day. J Altern Complement Med 2009, 15:929-934. 10.1089/acm.2008.0152, 3155102, 19678785.
24. Schutz K, Carle R, Schieber A. Taraxacum--a review on its phytochemical and pharmacological profile. J Ethnopharmacol 2006, 107:313-323. 10.1016/j.jep.2006.07.021, 16950583.
25. Chatterjee SJ, Ovadje P, Mousa M, Hamm C, Pandey S. The efficacy of dandelion root extract in inducing apoptosis in drug-resistant human melanoma cells. Evid Based Complement Alternat Med 2011, 2011:129045. 3018636, 21234313.
26. Ovadje P, Chatterjee S, Griffin C, Tran C, Hamm C, Pandey S. Selective induction of apoptosis through activation of caspase-8 in human leukemia cells (Jurkat) by dandelion root extract. J Ethnopharmacol 2011, 133:86-91. 10.1016/j.jep.2010.09.005, 20849941.
27. Lindsten K, Uhlikova T, Konvalinka J, Masucci MG, Dantuma NP. Cell-based fluorescence assay for human immunodeficiency virus type 1 protease activity. Antimicrob Agents Chemother 2001, 45:2616-2622. 10.1128/AAC.45.9.2616-2622.2001, 90701, 11502538.
28. Blair WS, Isaacson J, Li X, Cao J, Peng Q, Kong GF, Patick AK. A novel HIV-1 antiviral high throughput screening approach for the discovery of HIV-1 inhibitors. Antiviral Res 2005, 65:107-116. 10.1016/j.antiviral.2004.11.001, 15708637.
29. Cao J, Isaacson J, Patick AK, Blair WS. High-throughput human immunodeficiency virus type 1 (HIV-1) full replication assay that includes HIV-1 Vif as an antiviral target. Antimicrob Agents Chemother 2005, 49:3833-3841. 10.1128/AAC.49.9.3833-3841.2005, 1195408, 16127060.
30. Kremb S, Helfer M, Heller W, Hoffmann D, Wolff H, Kleinschmidt A, Cepok S, Hemmer B, Durner J, Brack-Werner R. EASY-HIT: HIV full-replication technology for broad discovery of multiple classes of HIV inhibitors. Antimicrob Agents Chemother 2010, 54:5257-5268. 10.1128/AAC.00515-10, 2981278, 20876377.
31. al Yacoub N, Romanowska M, Haritonova N, Foerster J. Optimized production and concentration of lentiviral vectors containing large inserts. J Gene Med 2007, 9:579-584. 10.1002/jgm.1052, 17533614.
32. Chkhikvishvili ID, Kharebava GI. Chicoric and chlorogenic acids in plant species from Georgia. Applied Biochemistry and Microbiology 2001, 37:188-191.
33. Kreis W, Kaplan MH, Freeman J, Sun DK, Sarin PS. Inhibition of Hiv Replication by Hyssop-Officinalis Extracts. Antiviral Research 1990, 14:323-337. 10.1016/0166-3542(90)90051-8, 1708226.
34. Aiken C. Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A. J Virol 1997, 71:5871-5877. 191842, 9223476.
35. Zhang H, Zhou Y, Alcock C, Kiefer T, Monie D, Siliciano J, Li Q, Pham P, Cofrancesco J, Persaud D, Siliciano RF. Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1. J Virol 2004, 78:1718-1729. 10.1128/JVI.78.4.1718-1729.2004, 369469, 14747537.
36. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, Tian H, Smith D, Winslow GA, Capon DJ, Whitcomb JM. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000, 44:920-928. 10.1128/AAC.44.4.920-928.2000, 89793, 10722492.
37. Adelson ME, Pacchia AL, Kaul M, Rando RF, Ron Y, Peltz SW, Dougherty JP. Toward the development of a virus-cell-based assay for the discovery of novel compounds against human immunodeficiency virus type 1. Antimicrob Agents Chemother 2003, 47:501-508. 10.1128/AAC.47.2.501-508.2003, 151745, 12543650.
38. Westby M, Nakayama GR, Butler SL, Blair WS. Cell-based and biochemical screening approaches for the discovery of novel HIV-1 inhibitors. Antiviral Res 2005, 67:121-140. 10.1016/j.antiviral.2005.06.006, 16112209.
39. Daelemans D, De Clercq E, Vandamme AM. A quantitative GFP-based bioassay for the detection of HIV-1 Tat transactivation inhibitors. J Virol Methods 2001, 96:183-188. 10.1016/S0166-0934(01)00330-5, 11445148.
40. Park IW, Han CR, Song XP, Green LA, Wang T, Liu Y, Cen CC, Song XM, Yang B, Chen GY, He JJ. Inhibition of HIV-1 entry by extracts derived from traditional Chinese medicinal herbal plants. Bmc Complementary and Alternative Medicine 2009, 9.
41. Dykes C, Demeter LM. Clinical significance of human immunodeficiency virus type 1 replication fitness. Clin Microbiol Rev 2007, 20:550-578. 10.1128/CMR.00017-07, 2176046, 17934074.